摘要
随着对结核病化学治疗研究的深入,尤其是短程化疗的问世,已可使85%以上初治肺结核患者痊愈,但由于耐药结核病,尤其是耐多药结核病(MDR-TB)的出现,使结核病又迅速成为全球性危机,开发、研制高效的新型抗结核药物已成为迫切任务。氟喹诺酮类药物无论在体内或体外均对结核分枝杆菌有一定的杀灭作用,可作为治疗MDR-TB的又一有力武器。
Along with the depening of the study on tuberculosis chemotherapy, in particular the short course chemotherapy being published, over 85% of the patients with pulmonary tuberculosis for primary treatment have convalesced. But because muhidrug-resistant tuberculosis （MDR-TB） appearances, MOR-TB becomes the global crisis rapidly. The development and study of highly effective, anti-tuberculosis new drug has become the urgent duty. Fluoroquinolone has certainly bactericidal function to mycobacterium tuberculosis in vivo and in vitro. It may be as a powerful weapon for treating MDR- TB.
出处
《中国药业》
CAS
2007年第6期25-27,共3页
China Pharmaceuticals
